"The Company continues to work towards its Investigational New...

"The Company continues to work towards its Investigational New Drug application for submission to the US FDA, which was initially planned for Q1:2024, but now likely to be delayed as Imagion works to ensure sufficient resources are in place to pursue clinical development of the MagSense® imaging technology. As the global first mover enabling molecular MRI, these results are very promising for Imagion and for improved precision oncology care. The Company is encouraged by the feedback IBI10103 results are attracting from prospective partners."

Looks like we are now seeking a partner for financial support to develop Magsense clinically.